

EP17-A2

Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition

This document provides guidance for evaluation and documentation of the detection capability of clinical laboratory measurement procedures (ie, limits of blank, detection, and quantitation), for verification of manufacturers' detection capability claims, and for the proper use and interpretation of different detection capability estimates.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

ISBN 1-56238-795-2 (Print)
ISBN 1-56238-796-0 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

EP17-A2
Vol. 32 No. 8
Replaces EP17-A
Vol. 24 No. 34

Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition

Volume 32 Number 8

James F. Pierson-Perry
Jeffrey E. Vaks, PhD
A. Paul Durham, MA
Christian Fischer, MD
Cornelius Gutenbrunner, PhD
David Hillyard, MD
Marina V. Kondratovich, PhD
Paula Ladwig
Robert A. Middleberg, PhD, DABFT, DABCC

Abstract

Clinical and Laboratory Standards Institute document EP17-A2—*Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition* provides guidance for evaluating the detection capability of clinical laboratory measurement procedures (ie, limits of blank, detection, and quantitation), for verification of manufacturers' detection capability claims, and for the proper use and interpretation of different detection capability estimates. EP17 is intended for use by manufacturers of *in vitro* diagnostic tests, regulatory bodies, and clinical laboratories.

Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition*. CLSI document EP17-A2 (ISBN 1-56238-795-2 [Print]; ISBN 1-56238-796-0 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2012.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



Copyright ©2012 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition*. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

Previous Editions:

March 2004, October 2004

Reaffirmed:

June 2017

ISBN 1-56238-795-2 (Print)
ISBN 1-56238-796-0 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Standard Precautions.....	1
3 Terminology.....	1
3.1 A Note on Terminology.....	1
3.2 Definitions.....	2
3.3 Abbreviations and Acronyms.....	4
4 Background.....	5
4.1 Overview of Detection Capability.....	5
4.2 Historical Perspectives.....	6
4.3 Current Status.....	8
4.4 Application to Qualitative Measurement Procedures.....	9
4.5 General Notes on Sample Selection.....	9
4.6 General Notes on Data Collection and Review.....	10
5 Protocols for Evaluation of the Limit of Blank and Limit of Detection.....	10
5.1 Introduction.....	10
5.2 Selection of Experimental Protocol.....	11
5.3 Classical Approach.....	12
5.4 Precision Profile Approach.....	18
5.5 Probit Approach.....	22
6 Protocol for Evaluation of the Limit of Quantitation.....	27
6.1 Introduction.....	27
6.2 Specification of Accuracy Goals.....	28
6.3 Experimental Design.....	29
6.4 Experimental Steps.....	30
6.5 Data Analysis.....	30
6.6 Variant Approach: Combined Limits of Detection and Quantitation Evaluation.....	31
7 Verification of Detection Capability Claims.....	32
7.1 Introduction.....	32
7.2 Verification of a Limit of Blank Claim.....	33
7.3 Verification of a Limit of Detection Claim.....	34
7.4 Verification of a Limit of Quantitation Claim.....	35
8 Reporting Detection Capability.....	36
8.1 Interpretations and Reporting Intervals for Quantitative Measurement Procedure Results.....	37
8.2 Example Labeling for Detection Capability Claims of Quantitative Measurement Procedures.....	39
References.....	40
Appendix A. Worked Example: Evaluation of Limits of Blank and Detection by the Classical Approach.....	42

Contents (Continued)

Appendix B. Worked Example: Evaluation of Limit of Detection by the Precision Profile Approach.....47

Appendix C. Worked Example: Evaluation of Limit of Detection by the Probit Approach51

Appendix D. Worked Examples: Evaluation of Limit of Quantitation.....54

Appendix E. Worked Example: Verification of Limits of Blank and Detection Claims60

Appendix F. Worked Example: Verification of Limit of Quantitation Claim61

The Quality Management System Approach62

Related CLSI Reference Materials63

SAMPLE

Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition

1 Scope

This document provides guidelines for the evaluation and verification of detection capability claims of clinical laboratory measurement procedures (ie, limit of blank [LoB], limit of detection [LoD], and limit of quantitation [LoQ]), as well as for their proper use, documentation, and interpretation. This guidance is suitable both for commercial products as well as laboratory-developed tests. It is particularly important for measurement procedures for which the associated measurand's medical decision level is low (ie, approaching zero).

The intended users of this guideline are manufacturers of *in vitro* diagnostic (IVD) reagents, regulatory bodies, and clinical laboratory personnel.

2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. The Centers for Disease Control and Prevention address this topic in published guidelines that focus on the daily operations of diagnostic medicine in human and animal medicine while encouraging a culture of safety in the laboratory.⁶ For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious diseases, refer to CLSI document M29.⁷

3 Terminology

3.1 A Note on Terminology

As a global leader in standardization, CLSI is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI's consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate the global application of standards and guidelines.

Because of the widespread application of the LoD and LoQ concepts, a variety of terms are in common usage. This document does not attempt to explain or reconcile all of these terms. Terms particular to this document are defined in Section 3.2. However, there are two common terms that have nonstandard usage in the clinical laboratory. To prevent confusion, these terms are discussed in Sections 3.1.1 and 3.1.2.

3.1.1 Nonstandard Use of “Critical Value”

The term “critical value” is defined in ISO 11843-1¹ as the highest result that can reasonably be expected from a blank sample (ie, a sample with concentration at or near zero) for a given error probability α . However, the term is widely used in clinical laboratories for test results that indicate an important medical condition (also sometimes referred to as “alarm value”). In this document, the ISO term is replaced by “LoB.”

3.1.2 Nonstandard Use of “Sensitivity”

The term “sensitivity” and its variants “analytical sensitivity” and “functional sensitivity” are not promoted in this document, because of the existence of several conflicting common uses of these terms across multiple technical disciplines. LoD is the preferred term for the detection capability attribute previously associated with analytical sensitivity (ie, signaling presence of a measurand in a sample) because of its more precise definition and common use. Similarly, LoQ is the preferred term for the detection capability attribute previously associated with functional sensitivity (ie, denoting quantitative detection of a measurand in a sample with known measurement accuracy).

3.2 Definitions

accepted reference value – a value that serves as an agreed-upon reference for comparison, and that is derived as a) a theoretical or established value, based on scientific principles; b) an assigned or certified value, based on experimental work of some national or international organization; c) a consensus or certified value, based on collaborative experimental work under the auspices of a scientific or engineering group; and d) when a), b), and c) are not available, the expectation of the (measurable) quantity, ie, the mean of a specified population of measurements (ISO 3534-1).⁸

accuracy – closeness of agreement between a test result and the accepted reference value; **NOTE:** The term “accuracy,” when applied to a set of test results, involves a combination of random components and a common systematic error or bias component (ISO 3534-1)⁸; see **true**ness.

analytical sensitivity – quotient of the change in a measurement indication and the corresponding change in a value of the quantity being measured (modified from JCGM 200:2012)⁹; **NOTE 1:** VIM uses the term “sensitivity of a measuring system” (JCGM 200:2012)⁹; **NOTE 2:** The analytical sensitivity of a measuring system is the slope of the calibration curve; **NOTE 3:** Analytical sensitivity should not be used to mean detection limit or quantitation limit, and should not be confused with diagnostic sensitivity (modified from ISO 18113-1).¹⁰

bias – difference between the expectation of the test results and an accepted reference value (ISO 3534-1)⁸; **NOTE:** Bias is a measure of **true**ness.

blank – sample that does not contain the analyte of interest, or has a concentration at least an order of magnitude less than the lowest level of interest.

censored data – the situation in which measurement results are simply reported as greater than or less than an imposed threshold rather than expressed in quantitative units; **NOTE:** For example, a result is known to be less than a stated limit but the actual result value is not available.

functional sensitivity – the measurand concentration at which precision of a measurement procedure, under stated experimental conditions, meets a stated performance requirement; **NOTE 1:** It is typically determined from a precision profile; **NOTE 2:** The term “limit of quantitation” with stated requirement for accuracy is recommended.

The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

- Organization
- Customer Focus
- Facilities and Safety
- Personnel
- Purchasing and Inventory
- Equipment
- Process Management
- Documents and Records
- Information Management
- Nonconforming Event Management
- Assessments
- Continual Improvement

EP17-A2 addresses the QSE indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Organization	Customer Focus	Facilities and Safety	Personnel	Purchasing and Inventory	Equipment	Process Management	Documents and Records	Information Management	Nonconforming Event Management	Assessments	Continual Improvement
		M29				X C51 EP05 EP06 EP07 EP12 EP14 EP15 MM03					EP07 MM03

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

EP17-A2 does not address any of the clinical laboratory path of workflow processes indicated in the grid below. For a description of the document listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Preexamination				Examination			Postexamination	
Examination ordering	Sample collection	Sample transport	Sample receipt/processing	Examination	Results review and follow-up	Interpretation	Results reporting and archiving	Sample management
	MM03	MM03	MM03	MM03	MM03		MM03	

Related CLSI Reference Materials*

- C51-A** **Expression of Measurement Uncertainty in Laboratory Medicine; Approved Guideline (2012).** This guideline describes a practical approach to assist clinical laboratories in developing and calculating useful estimates of measurement uncertainty, and illustrates their application in maintaining and improving the quality of measured values used in patient care. A CLSI-IFCC joint project.
- EP05-A2** **Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition (2004).** This document provides guidance for designing an experiment to evaluate the precision performance of quantitative measurement methods; recommendations on comparing the resulting precision estimates with manufacturers' precision performance claims and determining when such comparisons are valid; as well as manufacturers' guidelines for establishing claims.
- EP06-A** **Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (2003).** This document provides guidance for characterizing the linearity of a method during a method evaluation; for checking linearity as part of routine quality assurance; and for determining and stating a manufacturer's claim for linear range.
- EP07-A2** **Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition (2005).** This document provides background information, guidance, and experimental procedures for investigating, identifying, and characterizing the effects of interfering substances on clinical chemistry test results.
- EP12-A2** **User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline—Second Edition (2008).** This document provides a consistent approach for protocol design and data analysis when evaluating qualitative diagnostic tests. Guidance is provided for both precision and method-comparison studies.
- EP14-A2** **Evaluation of Matrix Effects; Approved Guideline—Second Edition (2005).** This document provides guidance for evaluating the bias in analyte measurements that is due to the sample matrix (physiological or artificial) when two measurement procedures are compared.
- EP15-A2** **User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition (2006).** This document describes the demonstration of method precision and trueness for clinical laboratory quantitative methods utilizing a protocol designed to be completed within five working days or less.
- M29-A3** **Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005).** Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.
- MM03-A2** **Molecular Diagnostic Methods for Infectious Diseases; Approved Guideline—Second Edition (2006).** This guideline addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors, and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.

Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.



By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI's efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.



Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.



When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.

SAMPLE



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

950 West Valley Road, Suite 2500, Wayne, PA 19087 USA

P: 610.688.0100 Toll Free (US): 877.447.1888 F: 610.688.0700

E: customerservice@clsi.org www.clsi.org

PRINT ISBN 1-56238-795-2

ELECTRONIC ISBN 1-56238-796-0